Updated:
Sirnaomics
Sirnaomics was founded in 2007 in Gaithersburg, Maryland, by a professional international team, and has since established offices in Las Vegas and...
Sirnaomics
Sirnaomics was founded in 2007 in Gaithersburg, Maryland, by a professional international team, and has since established offices in Las Vegas and Shenzhen, China. The firm's wealth origin is undisclosed, as it remains a publicly traded clinical-stage biopharmaceutical company. Its strategy centers on two proprietary delivery platforms: the PNP platform for mRNA therapeutics vaccines, and a GalNAc delivery system for liver-targeted RNAi therapies. The pipeline includes STP705 (Phase II for skin conditions and oncology), STP122G (Phase I for anticoagulation via FXI siRNA), and a dual-targeted muRNA program. Sirnaomics focuses on cancers, fibrosis, antivirals, cardiometabolic diseases, and medical aesthetics, with clinical data spanning both U.S. and Chinese sites. The firm employs a professional team across its U.S. and China locations, though exact headcount is undisclosed. No recent operational event from the last 24 months was identified. There are no known philanthropic arms or adjacent vehicles. Sirnaomics structurally differentiates itself by being one of the few firms with clinical validation for extrahepatic RNA delivery via its PNP platform (per the firm, 2024). Its dual-region setup in the U.S. and China for both operations and trials is unusual among RNA therapeutics companies.
General information
Firm type
other
Year founded
2007
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Gaithersburg
Corporate office
Gaithersburg, MD, United States
Additional offices
Las Vegas, NV, United States · Shenzhen, China
Sector focus
Frequently asked questions
Who runs investment decisions at Sirnaomics?
The firm does not publicly disclose a single named investment principal. As a clinical-stage biopharmaceutical company, capital allocation decisions are made by its professional management team, likely under the oversight of the board of directors (per the firm).
Does Sirnaomics operate as a family office or a biopharma company?
Sirnaomics is a publicly traded clinical-stage biopharmaceutical company, not a family office. It is included here due to its organizational structure and investment allocation via its corporate capital.
What investment stages does Sirnaomics typically target?
Sirnaomics allocates capital to internal R&D and clinical trials for its own pipeline, rather than making external investments. Its stage coverage spans preclinical through Phase IIb clinical trials, as seen with programs like STP705 and STP122G (per the firm).
Which sectors does Sirnaomics explicitly avoid?
The firm focuses exclusively on RNA therapeutics for cancers, fibrosis, antivirals, cardiometabolic diseases, and medical aesthetics. It has no disclosed exposure to traditional asset classes like real estate, private equity, or hedge funds.
How does Sirnaomics source proprietary deal flow?
Sirnaomics does not source external deal flow; its pipeline is built internally using its two proprietary delivery platforms, PNP and GalNAc (per the firm).
Is Sirnaomics structured as a single family office or does it operate more like a venture firm?
Sirnaomics is a clinical-stage biopharmaceutical company with a corporate structure. It does not operate as a single or multi-family office, nor as a venture firm.
Does Sirnaomics participate in fund commitments or only direct deals?
Sirnaomics does not commit to external funds; its capital is deployed directly into its own R&D and clinical development programs.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: